Alembic Pharmaceuticals Limited announced a competitive win with the FDA approval of its Tretinin topical ANDA, allowing it to enter the market and challenge established players amid fluctuating generic demand for acne treatments. This approval strengthens Alembic’s generic portfolio and offers a potential supply alternative just as the acne drug market anticipates peak utilization.